

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
Date of first issue: 30.09.2019

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Manufacturer or supplier's details

Company : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use


Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Eye irritation : Category 2A
Reproductive toxicity : Category 1A
Specific target organ toxicity - repeated exposure : Category 2 (Kidney, Parathyroid gland)
Short-term (acute) aquatic hazard : Category 3
Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H319 Causes serious eye irritation.
H360D May damage the unborn child.
H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
H412 Harmful to aquatic life with long lasting effects.

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
Date of first issue: 30.09.2019

Precautionary Statements

- Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:**
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
- Storage:**
P405 Store locked up.
- Disposal:**
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

- May form explosible dust-air mixture if dispersed.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 50
Starch	9005-25-8	>= 30 -< 50
Olmesartan	144689-63-4	>= 10 -< 20
Hydrochlorothiazide	58-93-5	>= 5 -< 10
Amlodipine Besylate	652969-01-2	>= 2,5 -< 5

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

-
- | | | |
|---|---|---|
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : | Causes serious eye irritation.
May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |
-

SECTION 5. FIRE-FIGHTING MEASURES

- | | | |
|--|---|---|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | High volume water jet |
| Specific hazards during fire fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Do not use a solid water stream as it may scatter and spread fire.
Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Nitrogen oxides (NO _x)
Chlorine compounds
Sulfur oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types: Strong oxidizing agents

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
Date of first issue: 30.09.2019

Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
		Further information: Irritation		
		TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	CMP	10 mg/m ³	AR OEL
		Further information: A4 - Not classifiable as a human carcinogen, lung, Dermatitis		
		TWA	10 mg/m ³	ACGIH
Olmesartan	144689-63-4	TWA	30 µg/m ³ (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Hydrochlorothiazide	58-93-5	TWA	100 µg/m ³ (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	tablet
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	No data available
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
Date of first issue: 30.09.2019

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Dust can form an explosive mixture in air.
Can react with strong oxidizing agents.

Conditions to avoid : Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
Date of first issue: 30.09.2019

||

Olmesartan:

|| Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Mouse): > 2.000 mg/kg
LD50 (Dog): > 1.500 mg/kg
|| Acute inhalation toxicity : Remarks: No data available
|| Acute dermal toxicity : Remarks: No data available

Hydrochlorothiazide:

|| Acute oral toxicity : LD50 (Rat): > 2.750 mg/kg
LD50 (Mouse): > 2.830 mg/kg
|| Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg
Application Route: Intravenous
LD50 (Mouse): 590 mg/kg
Application Route: Intravenous

Amlodipine Besylate:

|| Acute oral toxicity : LD50 (Rat): 393 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Olmesartan:

|| Remarks : No data available

Hydrochlorothiazide:

|| Species : Rabbit
|| Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Starch:

|| Species : Rabbit
|| Result : No eye irritation

Olmesartan:

|| Species : Rabbit

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

Result	: Moderate eye irritation
Method	: Draize Test

Hydrochlorothiazide:

Species	: Rabbit
Result	: Mild eye irritation

Amlodipine Besylate:

Species	: Rabbit
Result	: Severe irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Starch:**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

Olmesartan:

Routes of exposure	: Skin contact
Remarks	: No data available

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
Genotoxicity in vivo	: Test Type: In vitro mammalian cell gene mutation test
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
	Species: Mouse
	Application Route: Ingestion
	Result: negative

Starch:

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Olmesartan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster lung cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Hydrochlorothiazide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster ovary cells
Result: positive

Test Type: in vitro test
Test system: mouse lymphoma cells
Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Chinese hamster
Cell type: Bone marrow
Result: negative

Test Type: in vivo assay
Species: Mouse
Cell type: Bone marrow
Result: negative

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

|| Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Amlodipine Besylate:

|| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Carcinogenicity

Not classified based on available information.

Components:
Cellulose:

|| Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Olmesartan:

|| Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

|| Species : Mouse
Application Route : Oral
Exposure time : 6 Months
Result : negative

Hydrochlorothiazide:

|| Species : Mouse, female
Application Route : Oral
Exposure time : 2 Years
Result : negative

|| Species : Mouse, male
Application Route : Oral
Exposure time : 2 Years
Result : equivocal

|| Species : Rat, male and female
Application Route : Oral
Exposure time : 2 Years
Result : negative

Amlodipine Besylate:

|| Species : Mouse

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

Reproductive toxicity

May damage the unborn child.

Components:**Cellulose:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on fetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

Olmesartan:

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 1.000 mg/kg body weight Result: No effects on fertility.
Effects on fetal development	:	Test Type: Development Species: Rat Application Route: Oral Dose: 1000 milligram per kilogram Result: No teratogenic effects. Test Type: Development Species: Rabbit Application Route: Oral Dose: 1 milligram per kilogram Result: No teratogenic effects. Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: >= 1,6 mg/kg body weight Symptoms: Malformations were observed., Reduced body weight Result: Effects on postnatal development.
Reproductive toxicity - As-	:	Positive evidence of adverse effects on development from

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0 Revision Date: 09.04.2021 SDS Number: 4944866-00004 Date of last issue: 10.10.2020
 Date of first issue: 30.09.2019

Assessment human epidemiological studies.

Hydrochlorothiazide:

Effects on fertility : Test Type: Fertility
 Species: Rat, male and female
 Application Route: oral (feed)
 Fertility: NOAEL: 4 mg/kg body weight
 Result: Effects on fertility.

Test Type: Fertility
 Species: Mouse, male and female
 Application Route: oral (feed)
 Fertility: NOAEL: 100 mg/kg body weight
 Result: Effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Mouse
 Application Route: Oral
 Developmental Toxicity: NOAEL: 3.000 mg/kg body weight
 Result: No teratogenic effects.

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
 Result: No teratogenic effects.

Amlodipine Besylate:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Fertility: NOAEL: 10 mg/kg body weight
 Result: No effects on fertility.

Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Ingestion
 Fertility: NOAEL: 25 mg/kg body weight
 Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: Effects on fetal development.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Ingestion
 Developmental Toxicity: NOAEL: 10 mg/kg body weight
 Result: No effects on fetal development.

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 1,6 mg/kg body weight
 Result: Effects on fetal development.
 Remarks: Maternal toxicity observed.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:

Target Organs : Kidney, Parathyroid gland
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
 NOAEL : ≥ 9.000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Starch:

Species : Rat
 NOAEL : ≥ 2.000 mg/kg
 Application Route : Skin contact
 Exposure time : 28 Days
 Method : OECD Test Guideline 410

Olmesartan:

Species : Rat
 NOAEL : 2.000 mg/kg
 Application Route : Oral
 Exposure time : 24 Months
 Remarks : No significant adverse effects were reported

Hydrochlorothiazide:

Species : Rat, male and female
 LOAEL : 10 mg/kg
 Application Route : Oral
 Exposure time : 2 y
 Target Organs : Kidney, Parathyroid gland

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

Species	: Mouse, male and female
NOAEL	: 300 - 550 mg/kg
Application Route	: Oral
Exposure time	: 2 y
Remarks	: No significant adverse effects were reported

Species	: Dog
	: 50 - 200 mg/kg
Application Route	: Oral
Exposure time	: 9 Months
Target Organs	: Parathyroid gland

Amlodipine Besylate:

Species	: Rat
NOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Remarks	: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Components:

Hydrochlorothiazide:

|| No aspiration toxicity classification

Experience with human exposure

Components:

Olmesartan:

Eye contact	: Symptoms: Eye irritation
Ingestion	: Symptoms: hypotension
	Remarks: May cause harm to the unborn child.
	Based on Human Evidence

Hydrochlorothiazide:

Eye contact	: Symptoms: Eye irritation
Ingestion	: Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

Amlodipine Besylate:

Eye contact	: Symptoms: Severe irritation
Ingestion	: Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Edema, Palpitation

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish	:	LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Hydrochlorothiazide:

Toxicity to fish	:	LC50 (<i>Pimephales promelas</i> (fathead minnow)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): > 500 mg/l Exposure time: 48 h

Amlodipine Besylate:

Toxicity to fish	:	LC50 (<i>Pimephales promelas</i> (fathead minnow)): 2,7 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): 3,2 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	IC50 (<i>Pseudokirchneriella subcapitata</i> (green algae)): 5,6 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Persistence and degradability

Components:

Cellulose:

Biodegradability	:	Result: Readily biodegradable.
------------------	---	--------------------------------

Hydrochlorothiazide:

Stability in water	:	Hydrolysis: 46,2 %(96 h)
--------------------	---	--------------------------

Bioaccumulative potential

Components:

Amlodipine Besylate:

Partition coefficient: n-octanol/water	:	log Pow: 3
--	---	------------

Mobility in soil

No data available

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version 2.0	Revision Date: 09.04.2021	SDS Number: 4944866-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
----------------	------------------------------	------------------------------	---

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

compile the Material Safety Data Sheet

eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944866-00004	Date of first issue: 30.09.2019

AR / Z8